Document is current
Any future updates will be listed below
-
Authors
Franzén, Lovisa https://orcid.org/0000-0003-3755-718X
Olsson Lindvall, Martina
Hühn, Michael
Ptasinski, Victoria https://orcid.org/0000-0002-2186-6634
Setyo, Laura
Keith, Benjamin P.
Collin, Astrid
Oag, Steven
Volckaert, Thomas
Borde, Annika
Lundeberg, Joakim https://orcid.org/0000-0003-4313-1601
Lindgren, Julia https://orcid.org/0000-0002-3566-2069
Belfield, Graham
Jackson, Sonya
Ollerstam, Anna
Stamou, Marianna https://orcid.org/0000-0003-0496-3229
Ståhl, Patrik L. https://orcid.org/0000-0002-2207-7370
Hornberg, Jorrit J.
-
Funding
Funding for this research was provided by:
Stiftelsen för Strategisk Forskning (ID18-0094, ID18-0094, ID18-0094)
AstraZeneca
- License Information
-
More Information
Article History
Received: 20 December 2023
Accepted: 30 May 2024
First Online: 1 July 2024
Competing interests
: The authors declare the following competing interests: P.L.S. and J. Lundeberg are scientific consultants to 10x Genomics. The remaining authors (L.F., M.O.L., M.H., V.P., L.S., B.P.K., A.C., S.O., T.V., A.B., J. Lindgren, G.B., S.J., A.O., M.S. and J.H.) are employees and/or stockholders of AstraZeneca.
